Takano Masato, Shimada Keiji, Fujii Tomomi, Morita Kohei, Takeda Maiko, Nakajima Yoshiyuki, Nonomura Akitaka, Konishi Noboru, Obayashi Chiho
Departments of Diagnostic Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.
Department of Pathology, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.
BMC Cancer. 2016 Nov 18;16(1):903. doi: 10.1186/s12885-016-2949-y.
Keratin (K) 19-positive hepatocellular carcinoma (HCC) is well known to have a higher malignant potential than K19-negative HCC: However, the molecular mechanisms involved in K19-mediated progression of HCC remain unclear. We attempted to clarify whether K19 directly affects cell survival and invasiveness in association with cellular senescence or epithelial-mesenchymal transition (EMT) in K19-positive HCC.
K19 expression was analysed in 136 HCC surgical specimens. The relationship of K19 with clinicopathological factors and survival was analysed. Further, the effect of K19 on cell proliferation, invasion, and angiogenesis was examined by silencing K19 in the human HCC cell lines, HepG2, HuH-7, and PLC/PRF/5. Finally, we investigated HCC invasion, proliferation, and angiogenesis using K19-positive HCC specimens.
Analysis of HCC surgical specimens revealed that K19-positive HCC exhibited higher invasiveness, metastatic potential, and poorer prognosis. In vitro experiments using the human HCC cell lines revealed that K19 silencing suppressed cell growth by inducting apoptosis or upregulating p16 and p27, resulting in cellular senescence. In addition, transfection with K19 siRNA upregulated E-cadherin gene expression, significantly inhibited the invasive capacity of the cells, downregulated angiogenesis-related molecules such as vasohibin-1 (VASH1) and fibroblast growth factor 1 (FGFR1), and upregulated vasohibin-2 (VASH2). K19-positive HCC specimens exhibited a high MIB-1 labelling index, decreased E-cadherin expression, and high microvessel density around cancer foci.
K19 directly promotes cancer cell survival, invasion, and angiogenesis, resulting in HCC progression and poor clinical outcome. K19 may therefore be a novel drug target for the treatment of K19-positive HCC.
众所周知,角蛋白(K)19阳性肝细胞癌(HCC)比K19阴性HCC具有更高的恶性潜能。然而,K19介导的HCC进展所涉及的分子机制仍不清楚。我们试图阐明K19是否与K19阳性HCC中的细胞衰老或上皮-间质转化(EMT)相关,直接影响细胞存活和侵袭性。
分析136例HCC手术标本中的K19表达情况。分析K19与临床病理因素及生存的关系。此外,通过在人HCC细胞系HepG2、HuH-7和PLC/PRF/5中沉默K19,研究K19对细胞增殖、侵袭和血管生成的影响。最后,我们使用K19阳性HCC标本研究HCC的侵袭、增殖和血管生成情况。
对HCC手术标本的分析显示,K19阳性HCC表现出更高的侵袭性、转移潜能和更差的预后。使用人HCC细胞系进行的体外实验表明,K19沉默通过诱导凋亡或上调p16和p27抑制细胞生长,导致细胞衰老。此外,用K19 siRNA转染上调E-钙黏蛋白基因表达,显著抑制细胞的侵袭能力,下调血管抑制素-1(VASH1)和成纤维细胞生长因子1(FGFR1)等血管生成相关分子,并上调血管抑制素-2(VASH2)。K19阳性HCC标本显示高MIB-1标记指数、E-钙黏蛋白表达降低以及癌灶周围微血管密度高。
K19直接促进癌细胞存活、侵袭和血管生成,导致HCC进展和不良临床结局。因此,K19可能是治疗K19阳性HCC的新型药物靶点。